Furosemide/Non-Steroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation
Metadatos
Afficher la notice complèteAuteur
Acebedo Martínez, Francisco Javier; Alarcón-Payer, Carolina; Rodríguez Domingo, Lucía; Domínguez Martín, Alicia; Gómez Morales, Jaime; Choquesillo Lazarte, DuaneEditorial
MDPI
Materia
Drug–drug cocrystal Furosemide Ethenzamide Piroxicam Mechanochemical synthesis
Date
2021Referencia bibliográfica
Acebedo-Martínez, F.J.; Alarcón-Payer, C.; RodríguezDomingo, L.; Domínguez-Martín, A.; Gómez-Morales, J.; ChoquesilloLazarte, D. Furosemide/NonSteroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation. Crystals 2021, 11, 1339. https://doi.org/10.3390/ cryst11111339
Patrocinador
y Spanish Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (MICIU) and co-funded with FEDER, UE, Project No. PGC2018- 102047-B-I00 (MCIU/AEI/FEDER, UE) and Project No. B-FQM-478-UGR20 (FEDER-Universidad de Granada, Spain).Résumé
The design of drug–drug multicomponent pharmaceutical solids is one the latest drug
development approaches in the pharmaceutical industry. Its purpose is to modulate the physicochemical properties of active pharmaceutical ingredients (APIs), most of them already existing in
the market, achieving improved bioavailability properties, especially on oral administration drugs.
In this work, our efforts are focused on the mechanochemical synthesis and thorough solid-state
characterization of two drug–drug cocrystals involving furosemide and two different non-steroidal
anti-inflammatory drugs (NSAIDs) commonly prescribed together: ethenzamide and piroxicam.
Besides powder and single crystal X-ray diffraction, infrared spectroscopy and thermal analysis,
stability, and solubility tests were performed on the new solid materials. The aim of this work was
evaluating the physicochemical properties of such APIs in the new formulation, which revealed
a solubility improvement regarding the NSAIDs but not in furosemide. Further studies need to be
carried out to evaluate the drug–drug interaction in the novel multicomponent solids, looking for
potential novel therapeutic alternatives.